ATE347552T1 - Cyclohexylaminderivate und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten - Google Patents

Cyclohexylaminderivate und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten

Info

Publication number
ATE347552T1
ATE347552T1 AT02006325T AT02006325T ATE347552T1 AT E347552 T1 ATE347552 T1 AT E347552T1 AT 02006325 T AT02006325 T AT 02006325T AT 02006325 T AT02006325 T AT 02006325T AT E347552 T1 ATE347552 T1 AT E347552T1
Authority
AT
Austria
Prior art keywords
chem
nmda receptor
formula
subtype
receptor antagonists
Prior art date
Application number
AT02006325T
Other languages
English (en)
Inventor
Russel Joseph Deorazio
Sham Shridhar Nikam
Ian Leslie Scott
Brian Alan Sherer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE347552T1 publication Critical patent/ATE347552T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02006325T 2001-03-27 2002-03-21 Cyclohexylaminderivate und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten ATE347552T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27916901P 2001-03-27 2001-03-27

Publications (1)

Publication Number Publication Date
ATE347552T1 true ATE347552T1 (de) 2006-12-15

Family

ID=23067927

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02006325T ATE347552T1 (de) 2001-03-27 2002-03-21 Cyclohexylaminderivate und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten

Country Status (9)

Country Link
US (1) US6828341B2 (de)
EP (1) EP1251128B1 (de)
JP (1) JP2002326988A (de)
AT (1) ATE347552T1 (de)
BR (1) BR0200988A (de)
CA (1) CA2378876A1 (de)
DE (1) DE60216535T2 (de)
ES (1) ES2275766T3 (de)
MX (1) MXPA02002749A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0111267A (pt) * 2000-06-06 2003-12-16 Warner Lambert Co Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda
EP1928866A1 (de) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituierte indazole als inhibitoren von phosphodiesterase typ-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JPWO2007063839A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 シクロヘキサン誘導体
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
PT2124944E (pt) 2007-03-14 2012-05-17 Ranbaxy Lab Ltd Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
US7998992B2 (en) 2007-03-30 2011-08-16 Institute Of Medicinal Molecular Design, Inc. Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
JP7083226B2 (ja) * 2016-06-10 2022-06-10 任天堂株式会社 ゲームコントローラ
MX2020008984A (es) 2018-02-28 2020-12-09 Dart Neuroscience Llc Compuestos de ciclohexilo sustituido como inhibidores de nop.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
WO1996034864A1 (en) * 1995-05-02 1996-11-07 Schering Corporation Piperazino derivatives as neurokinin antagonists
DE19739332C1 (de) 1997-09-09 1998-11-26 Merck Patent Gmbh Piperidinylmethyloxazolidinon-Derivat
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP0982026B1 (de) * 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern
MXPA02011926A (es) * 2000-05-31 2003-04-22 Warner Lambert Co Ciclohexilaminas biciclicas y su uso como antagonistas de receptor de n-metil-d-aspartato.

Also Published As

Publication number Publication date
ES2275766T3 (es) 2007-06-16
EP1251128A1 (de) 2002-10-23
JP2002326988A (ja) 2002-11-15
US6828341B2 (en) 2004-12-07
EP1251128B1 (de) 2006-12-06
DE60216535D1 (de) 2007-01-18
DE60216535T2 (de) 2007-07-05
BR0200988A (pt) 2003-01-14
CA2378876A1 (en) 2002-09-27
US20030004212A1 (en) 2003-01-02
MXPA02002749A (es) 2002-10-28

Similar Documents

Publication Publication Date Title
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
WO2002050070A3 (en) Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
BG106481A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumour agents
CA2167198A1 (en) Benzylaminoquinuclidines
CA2383779A1 (en) N-(indolecarbonyl)piperazine derivatives
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
NZ330624A (en) 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
BRPI0408988A (pt) composto de piperidinilamino-tieno[2,3-d]pirimidina
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
DE60216535D1 (de) Cyclohexylaminderivate und ihre Verwendung als Subtyp-selektive nmda Rezeptor Antagonisten
EP1465625A4 (de) Löslich gemachte topoisomerase-gifte
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
TW200510378A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
EP2258372B8 (de) A2A Antagonisten zur Behandlung von motorischen Störungen
CA2375671A1 (en) 4-phenyl-pyrimidine derivatives
EP1817311A4 (de) 2,3,4,6-substituierte pyridylderivat-verbindungen als beta-sektretase-inhibitoren zur behandlung von morbus alzheimer
EP1453507A4 (de) Solubilisierte topoisomerase-gift-mittel
ATE370147T1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
WO2002014275A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties